Based on data from the Phase 2 randomised controlled trial published in The New England Journal of Medicine in 2023, the timeline for seeing meaningful results with retatrutide generally follows a predictable pattern, though individual responses vary considerably depending on dose, titration schedule, and personal factors
Phenotype and genotype variation in primary carnitine deficiency
37 , D412D416 (2009)
What company makes Googeer GLP-1
Because the dose is small, the cost is too
But until insurance companies begin to cover them, or hospitals are willing to try via some sort of pilot project to see if we can do cost containment for them, I think were going to sort of be stuck where we are, which is compounded therapies are right for patients who can afford them, but they are not as widely used as they might be. While direct copies of GLP-1 drugs can no longer be compounded on account of the FDA declaring an end to the shortage, compounding pharmacies can still produce and dispense custom formulations of the drug if prescribed by a doctor
